Comparison of Prandial AIR Inhaled Insulin Alone to Intensified Insulin Glargine Alone and to AIR Insulin Plus Intensified Insulin Glargine in Patients with Type 2 Diabetes Previously Treated with Once-Daily Insulin Glargine

Abstract

Background:

Patients with type 2 diabetes often initiate insulin with once-daily basal insulin. Over time, many patients intensify their insulin regimens in an attempt to attain and sustain glycemic targets. This study compares three intensification approaches: changing insulin glargine to preprandial AIR^® inhaled insulin (developed by Alkermes, Inc. [Cambridge, MA] and Eli Lilly and Company [Indianapolis, IN]; AIR is a registered trademark of Alkermes, Inc.), intensifying glargine via validated titration algorithms (IG), or adding AIR insulin while intensifying glargine (AIR + IG).

Methods:

Five hundred sixty patients with hemoglobin A_1c (A1C) of 7.5–10.5%, on one or more antihyperglycemic medications, and on once-daily insulin glargine for ≥4 months were randomly allocated to one of the three treatments lasting 52 weeks. The primary objective assessed between-group differences in A1C mean change from baseline to 24 weeks using last-observation-carried-forward (LOCF) in the intent-to-treat population.

Results:

At 24 weeks, A1C was reduced from a mean baseline of 8.5% to 7.7%, 7.9%, and 7.5% for the AIR, IG, and AIR + IG groups, respectively. AIR produced 0.20% greater A1C decrease than IG (least-squares mean difference = −0.20%; 95% confidence interval [CI], −0.39, −0.02). AIR + IG had a 0.35% greater A1C decrease versus IG (95% CI, −0.57, −0.13). The −0.15% difference between AIR + IG versus AIR was not significant (P < 0.198). More hypoglycemia categorized as severe occurred with AIR alone versus IG alone at LOCF end points. More nocturnal hypoglycemia occurred with IG alone versus AIR alone and AIR + IG.

Conclusions:

Preprandial inhaled insulin provides an alternative for patients not optimized on insulin glargine alone. Glycemic control, hypoglycemic risk, delivery preference, and regimen complexity must be considered when selecting insulin initiation and optimization regimens.